• Abstract

    Immunosuppressive medications have the area of organ transplantation. Repurposing these medications for the treatment of cancer recent years. In the context of cancer therapy, the use of immunosuppressive medications such as cyclosporine, tacrolimus, sirolimus, mycophenolate acid mofetil (MMF), mycophenolate, and azathioprine is discussed. Treatment for cancer frequently includes methods designed to use the immune system to find and destroy cancer cells. Cancer cells can, however, avoid immune surveillance and eradication because the tumour microenvironment frequently has immune-suppressive components. Drugs that suppress the immune system, which were initially designed to avoid organ rejection, have demonstrated potential for obstructing these inhibitory pathways and boosting anti-tumour immune responses.Tacrolimus and cyclosporine, two immunosuppressive medications frequently used in transplantation, for their potential anti-cancer properties. The immune system and stifling tumour-promoting inflammatory responses, they can prevent tumour growth, angiogenesis, and metastasis. Another immunosuppressive drug, sirolimus, has shown anti-cancer effects by reducing angiogenesis and tumour cell growth while promoting immune-mediated tumour. It is well recognised that mycophenolate medicines, such as MMF and mycophenolate, have strong immunosuppressive properties. By inhibiting the enzyme responsible for purine production, they aim to inhibit lymphocyte proliferation. By altering immune cell function and reducing tumour growth, these medications have demonstrated promise in the treatment of cancer. Azathioprine, a medication that suppresses the immune system and is frequently used to treat autoimmune illnesses, has also been investigated as a possible cancer treatment. Although immunosuppressive medications have potential in the treatment of cancer, their usage needs to be carefully addressed due to potential side effects and the delicate balance between immune suppression and anti-tumour action. The immune system plays a crucial role in identifying and eliminating abnormal cells, including those associated with cancer.

  • References

    1. Sprague RG, Power MH: Observations on the physiologic effects of cortisone and ACTH in man. . Arch Intern Med. 1950, 85:199. 10.1001/archinte.1950.00230080003001
    2. Borel JF, Feurer C, Gubler HU, Stähelin H.: Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions. 1976, 6:468-75. 10.1007/BF01973261
    3. Classical and rational approaches to antifungal drug design. The university of queensland. (2017-2023). Accessed: September 26 2023: https://espace.library.uq.edu.au/view/UQ:691496.
    4. Denman AM: Immunosuppression and the rheumatic diseases. Ann Rheum Dis. 1982, 41:3-8. 10.1136/ard.41.Suppl_1.3
    5. Kemmner S, Guba MO, Schönermarck U, Stangl M, Fischereder M: Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection. Kidney Int. 2020, 98:507-8. 10.1016/j.kint.2020.05.024
    6. Karen R: For organ transplant recipients, cancer threatens long-term survival. JNCI. 2007, 99:421-422. 10.1093/jnci/djk141
    7. Chakkera HA, Kudva Y, Kaplan B: Calcineurin inhibitors: Pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. Clin Pharmacol Ther. 2017, 101:114-20. 10.1002/cpt.546
    8. Liddicoat AM, Lavelle EC: Modulation of innate immunity by cyclosporine A. Biochem Pharmacol. 2019, 163:472-80. 10.1016/j.bcp.2019.03.022
    9. Masi S, Uliana M, Gesi M, Taddei S, Virdis A: Drug-induced hypertension: Know the problem to know how to deal with it. Vascul Pharmacol. 2019, 115:84-8. 10.1016/j.vph.2019.02.002
    10. Pradier A, Papaserafeim M, Li N, et al.: Small-molecule immunosuppressive drugs and therapeutic immunoglobulins differentially inhibit NK cell effector functions in vitro. Front Immunol. 2019, 10:556. 10.3389/fimmu.2019.00556
    11. Pal P, Giri PP, Sinha R: Cyclosporine in resistant systemic arthritis - A cheaper alternative to biologics. Indian J Pediatr. 2019, 86:590-4. 10.1007/s12098-019-02912-9
    12. Shin HS, Grgic I, Chandraker A: Novel targets of immunosuppression in transplantation. Clin Lab Med. 2019, 39:157-69. 10.1016/j.cll.2018.10.008
    13. Yu M, Liu M, Zhang W, Ming Y: Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018, 19:513-22. 10.2174/1389200219666180129151948
    14. Yoshikawa N, Yokota T, Matsuo A, Matsumoto N, Iwakiri T, Ikeda R: Role of FK506 binding protein on tacrolimus distribution in red blood cells. Pharm Res. 2020, 13:143. 10.1007/s11095-020-02875-z
    15. Kalt DA: Tacrolimus: A review of laboratory detection methods and indications for use. Lab Med. 2017, 8:62-5. 10.1093/labmed/lmx056
    16. Dordal Culla MT, Herrera-Lasso Regás V, Martí-Garrido J, Rodríguez Cumplido D, Vázquez-Revuelta P, Lleonart Bellfill R: Treating COVID- 19: Review of drug hypersensitivity reactions. J Investig Allergol Clin Immunol. 2020, 30:385-99. 10.18176/jiaci.0588
    17. Fröhlich E: Understanding and preventing adverse effects of tacrolimus metabolization in transplant patients. Curr Drug Metab. 2019, 20:1039-40. 10.2174/1389200219666180806154433
    18. Jouve T, Noble J, Rostaing L, Malvezzi P: An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. Expert Opin Drug Saf. 2019, 18:285-94. 10.1080/14740338.2019.1599858
    19. Moes DJAR, Guchelaar HJ, de Fijter JW: Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015, 20:1243-9. 10.1016/j.drudis.2015.05.006
    20. Vitiello D, Neagoe PE, Sirois MG, White M: Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation. Cell Mol Immunol. 2015, 12:40-52. 10.1038/cmi.2014.24
    21. Yoon HY, Hwang JJ, Kim DS, Song JW: Efficacy and safety of low-dose sirolimus in lymphangioleiomyomatosis. Orphanet J Rare Dis. 2018, 14:204. 10.1186/s13023-018-0946-8
    22. Merkel S, Mogilevskaja N, Mengel M, Haller H, Schwarz A: Side effects of sirolimus. Transplant Proc. 2006, 38:714-5. 10.1016/j.transproceed.2006.01.044
    23. Adams DM, Trenor CC, Hammill AM, et al.: Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016, 137:32-57. 10.1542/peds.2015-3257
    24. Moes DJAR, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ: Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012, 51:467-80. 10.2165/11599710-000000000-00000
    25. Bilbao I, Salcedo M, Gómez MA, et al.: Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in spain. Liver Transpl. 2015, 21:1056-65. 10.1002/lt.24172
    26. Saliba F, Dharancy S, Lorho R, et al.: Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2011, 17:905-13. 10.1002/lt.22292
    27. Casanovas T, Argudo A, Peña-Cala MC: Everolimus in clinical practice in long-term liver transplantation: An observational study. Transplant Proc. 2011, 43:2216-9. 10.1016/j.transproceed.2011.06.015
    28. Tönshoff B, David-Neto E, Ettenger R, et al.: Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev Orlando Fla. 2011, 25:78-89. 10.1016/j.trre.2011.01.001
    29. Park H: The emergence of mycophenolate mofetil in dermatology. J Clin Aesthetic Dermatol. 4:18-27.
    30. Sagcal-Gironella ACP, Fukuda T, Wiers K, et al.: Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011, 40:307-13. 10.1016/j.semarthrit.2010.05.007
    31. Broen JCA, van Laar JM: Mycophenolate mofetil, azathioprine and tacrolimus: Mechanisms in rheumatology. Nat Rev Rheumatol. 2020, 16:167-78. 10.1038/s41584-020-0374-8
    32. Kaltenborn A, Schrem H: Mycophenolate mofetil in liver transplantation: A review. Ann Transplant. 2013, 18:685-96. 10.12659/AOT.889299
    33. Dias-Polak D, Bergman R, Avitan-Hersh E: Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis. J Dermatol Treat. 2019, 30:49-51. 10.1080/09546634.2018.1468068
    34. Horneff G: Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015, 14:1111-26. 10.1517/14740338.2015.1042453
    35. Björnsson ES, Gu J, Kleiner DE, Chalasani N, Hayashi PH, Hoofnagle JH: Azathioprine and 6-mercaptopurine-induced liver injury: Clinical features and outcomes. J Clin Gastroenterol. 2017, 51:63-9. 10.1097/MCG.0000000000000568
    36. Montante A, Le Bras A, Pagnoux C, et al.: Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2019, 117:137-43.
    37. Fuggle NR, Bragoli W, Mahto A, Glover M, Martinez AE, Kinsler VA: The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol. 2015, 72:108-14. 10.1016/j.jaad.2014.08.048
    38. Ghalamkari M, Karimpour Reyhan S, Khajavi Rad N, Abbaszadeh M.: Azathioprine-induced severe bone marrow suppression. Case Reports in Clin Pract. 2019, 4:9-13. 10.18502/crcp.v4i1.1300
    39. Risk factors: Immunosuppression. (2015). Accessed: September 26 2023: https://www.cancer.gov/about-cancer/causes-prevention/risk/immunosuppression.
    40. Setlai BP, Hull R, Bida M, et al.: Immunosuppressive signaling pathways as targeted cancer therapies. Biomedicines. 2022, 16:682. 10.3390/biomedicines10030682
    41. Weaver JL: Establishing the carcinogenic risk of immunomodulatory drugs. Toxicol Pathol. 20121, 40:267-71. 10.1177/0192623311427711
    42. Vial T, Descotes J: Immunosuppressive drugs and cancer. Toxicology. 2003, 1:229-40. 10.1016/s0300-483x(02)00612-1
    43. Cangemi M, Montico B, Faè DA, Steffan A, Dolcetti R: Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients. Front Oncol. 2019, 27:160. 10.3389/fonc.2019.00160
    44. Reyes A, Mohanty A, Pharaon R, Massarelli E: Association between immunosuppressive therapy utilized in the treatment of autoimmune disease or transplant and cancer progression. Biomedicines. 2023, 11:99. 10.3390/biomedicines11010099
    45. Tie Y, Tang F, Wei Y quan, Wei X wei: Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets. J Hematol Oncol. 2022, 18:61. 10.1186/s13045-022-01282-8

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Multidisciplinary Reviews

How to cite

Karmore, S., Mude, G., & Date, P. (2024). Immunosuppressive drug and cancer risk. Multidisciplinary Reviews, (| Accepted Articles). Retrieved from https://malque.pub/ojs/index.php/mr/article/view/3591
  • Article viewed - 22